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Abstract
Despite improvements in critical care, acute respiratory distress syndrome (ARDS) remains a devastating clinical
problem with high rates of morbidity and mortality. A better understanding of the prognostic factors associated
with ARDS is crucial for facilitating risk stratification and developing new therapeutic interventions that aim to
improve clinical outcomes. In this article, we present an up-to-date summary of factors that predict mortality in
ARDS in four categories: (1) clinical characteristics; (2) physiological parameters and oxygenation; (3) genetic
polymorphisms and biomarkers; and (4) scoring systems. In addition, we discuss how a better understanding of
clinical and basic pathogenic mechanisms can help to inform prognostication, decision-making, risk stratification,
treatment selection, and improve study design for clinical trials.
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Introduction
The acute respiratory distress syndrome (ARDS) is a
devastating syndrome of pulmonary inflammation and
edema manifested clinically by the acute onset of bilat-
eral infiltrates on chest radiograph, and arterial hypox-
emia [1–3]. Despite advances in the care of critically ill
patients, both short and long-term mortality rates of
ARDS remain high [4]. Currently, the only therapy that
has been definitively proven to reduce mortality in
ARDS is a lower tidal volume ventilator strategy [5].
However, other therapies have been shown to reduce
mortality in a subset of patients with ARDS. For ex-
ample, application of prone positioning in patients with
severe ARDS (defined for this study as a ratio of the par-
tial pressure of arterial oxygen to the fraction of inspired
oxygen [PaO2/FiO2] of less than 150 mm Hg) signifi-
cantly decreased 28-day and 90-day mortality [6]. Thus,
a better understanding of prognostic factors in ARDS is
crucial for facilitating risk stratification and developing
new therapeutic interventions that aim to improve clin-
ical outcomes. The aim of this article is to review known
clinical predictors and biologic markers of mortality in
ARDS. We categorize the prognostic factors into four
areas including (1) clinical characteristics; (2) physio-
logical parameters and oxygenation; (3) genetic polymor-
phisms and biomarkers; and (4) scoring systems. In
addition, we discuss how a better understanding of
clinical and basic pathogenic mechanisms can help to in-
form prognostication, decision-making, risk stratifica-




There have been a number of large studies over the past
several decades that have explored clinical risk factors
for hospital and short-term mortality in ARDS. Clinical
predictors that were consistent across multiple studies
include older age, worse physiologic severity of illness
(as measured by severity scores such as the Acute
Physiology and Chronic Health Evaluation (APACHE) or
Simplified Acute Physiology Score (SAPS)), shock on
hospital admission, arterial pH less than 7.30, liver dis-
ease, early air leak, immunosuppression, triggering risk
factor, and right ventricular dysfunction [7–11]. It is
important to note that these studies were all done before
the era of lower tidal volume ventilation. In more recent
studies done in clinical trial patient populations after the
widespread implementation of low tidal volume
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ventilation, severity of illness as measured by APACHE
II or APACHE III has remained a robust clinical pre-
dictor of mortality as have age, and the presence of non-
pulmonary organ failures [12, 13].
In regards to effects of race and ethnicity on mortality
from ARDS, a retrospective cohort study from the Na-
tional Institutes of Health (NIH) ARDS Network re-
vealed that African American and Hispanic patients
have a higher mortality from ARDS than Caucasian
patients [14]. The mechanisms that underlie this racial
disparity in mortality are unknown; one proposed factor
is related to the high incidence of a mutation in the pro-
moter region of the Duffy antigen/receptor for chemo-
kines (Darc) gene in those of African ancestry that leads
to low levels of erythrocyte Duffy antigen, reduced
chemokine binding and potentially to higher levels of
circulating chemokines such as IL-8 [15]. In a large mul-
ticenter study, Lemos-Filho LB et al. found that African-
American patients were less likely to develop ARDS than
Caucasians even after adjustment for clinical predictors
despite having higher severity of illness at presentation.
In the same study, there was no difference in ARDS
mortality by sex or race after adjustment for covariates
[16]. Recently, Reilly et al. reported that blood type A is
a risk factor for ARDS in Caucasian patients with major
trauma and sepsis [17]. However, it is not known
whether the same blood type is also associated with poor
prognosis in ARDS and this study has yet to be validated
in another patient population.
The role of diabetes in the development of ARDS is
still controversial. Koh et al. showed that diabetes melli-
tus is not associated with development of ARDS in a
large cohort of critically ill patients [18], although pa-
tients with diabetes had higher mortality regardless of
ARDS status. By contrast Yu et al. reported a protective
effect of diabetes on development of ARDS [19], but dia-
betes had no association with outcomes.
Most of the original studies of clinical risk factors for
mortality in ARDS have focused on short-term outcomes
such as hospital or 28-day mortality. However, it is in-
creasingly clear that long-term mortality after ARDS and
other critical illness is substantially higher than short-
term mortality; long-term mortality may be driven by
different factors than short-term. A multi-intensive care
unit, prospective cohort study of 646 patients hospital-
ized with ARDS showed that mortality at 1 year was
substantially higher than in-hospital mortality (41 % vs.
24 %, p < 0.001). The independent predictors of death at
1 year were age, living somewhere other than home
prior to admission, and serious comorbidities such as
HIV and malignancy [20]. For very severe ARDS patients
requiring extracorporeal membrane oxygenation
(ECMO) intervention, Schmidt et al. constructed a mor-
tality prediction model with eight pre-ECMO
parameters, i.e., age, body mass index, immunocom-
promised status, prone positioning, days of mechanical
ventilation, sepsis-related organ failure assessment, plat-
eau pressure and positive end-expiratory pressure; this
scoring system accurately predicted long term mortality
in this select group of severely ill ARDS patients [21].
Physiological parameters and oxygenation
Physiological parameters
A variety of physiological parameters are associated with
adverse outcomes in patients with ARDS. In the land-
mark study of lower tidal volume ventilation for ARDS
from the NIH ARDS Clinical Trials Network, inspiratory
plateau pressures were significantly lower on days 1, 3,
and 7 in the group treated with lower tidal volumes with
lower mortality compared to the group treated with
higher tidal volumes with higher mortality [5]. In the
ALVEOLI study of two different levels of positive end
expiratory pressure in ARDS, the alveolar-arterial oxygen
gradient and inspiratory plateau pressure were good pre-
dictors for mortality in ARDS patients [22]. Further-
more, Nuckton et al. found that pulmonary dead-space
fraction, which was calculated by the mean expired car-
bon dioxide fraction and was measured with a bedside
metabolic monitor, was an independent risk factor for
death [23]. Several subsequent studies have also reported
that an elevated ratio of pulmonary dead space to tidal
volume (VD /VT) within 24 h of onset of ARDS was
associated with higher mortality [24, 25]. Elevated pul-
monary dead space fraction likely reflects the extent of
pulmonary microvascular thrombosis and injury or frank
destruction of the pulmonary vascular bed, providing an
important index of the severity of acute lung injury.
Beyond respiratory parameters, there is controversial
data regarding the effect of right heart failure on the
prognosis of ARDS. In a large multicenter cohort study
in Europe, a higher ratio of right over left ventricular
stroke work (RVSW/LVSW) at admission was independ-
ently associated with mortality [26]. However, in a ran-
domized control study with a total of 145 ARDS patients
receiving pulmonary artery catheters (PAC), there was
no difference in 90-day mortality between patients with
and without right ventricular failure (71 vs. 67 %, re-
spectively) [27]. Again, it should be noted that the first
study was done before the era of low tidal volume venti-
lation; ventilation with higher tidal volumes and higher
pulmonary distending pressures may have had adverse
effects on right heart function that were not as apparent
in the more recent study. In another study in the low
tidal volume ventilation era, Bull et al. demonstrated
that pulmonary vascular dysfunction, which they defined
as elevated transpulmonary gradient and pulmonary
vascular resistance index measured by PAC in patients
enrolled in the NIH ARDS Network Fluid and Catheter
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Treatment Trial [28], was an independent risk factor for
60-day mortality [29].
Oxygenation
It seems intuitive that the severity of hypoxemia should
be associated with adverse outcomes in ARDS. However,
over the past two decades, several studies have shown
that the PaO2/FiO2 measured at the onset of ARDS is
not an independent predictor of mortality [9, 30–34].
One possible explanation for the inability of initial
PaO2/FiO2 to discriminate adverse outcomes in ARDS is
that the PaO2/FiO2 varies depending on ventilator strat-
egy. Indeed, manipulation of ventilator settings including
tidal volume (Vt) and positive end expiratory pressure
(PEEP) can greatly influence the values of PaO2/FiO2
[35]. Since PaO2/FiO2 is so sensitive to ventilator set-
tings, some investigators have asked whether the prog-
nostic value of PaO2/FiO2 might improve with
standardized ventilator settings. In a prospective, multi-
center study of 452 ARDS patients with PaO2/FiO2 mea-
sured on standard ventilator settings of volume assist/
control mode, tidal volume 7 ml/kg PBW, inspiratory:
expiratory time ratio (I:E) <1:1, ventilator rate to main-
tain PaCO2 of 35–50 mmHg and FiO2 and PEEP settings
applied in the following order: (1) FiO2 ≥ 0.5 with
PEEP ≥ 5 cmH2O, (2) FiO2 ≥ 0.5 with PEEP ≥ 10 cmH2O,
(3) FiO2 = 1.0 with PEEP ≥ 5 cmH2O, and (4) FiO2 = 1.0
with PEEP ≥ 10 cmH2O, risk stratification of ARDS was
substantially improved. Of these settings, only the PaO2/
FiO2 ratio measured using PEEP ≥ 10 cmH2O and
FiO2 ≥ 0.5 at 24 h after ARDS onset showed substantial
improvement in risk stratification for short term ARDS
mortality [36]. The finding is also consistent with ana-
lyses published with the Berlin ARDS definition; mortal-
ity prediction in ARDS was better when based not only
on PaO2/FiO2, but also on PEEP level and the extent of
lung infiltrates in chest radiograph [1]. Bone et al.
showed that early improvement of PaO2/FiO2 with con-
ventional therapy is a prognostic factor of better out-
come in patients with ARDS [30]. In addition, the
oxygenation response to the titration of PEEP or other
ventilator settings, such as high-frequency oscillatory
ventilation, may also be prognostically useful in ARDS
[37, 38]. Based on these findings, clinical trials that use
the PaO2/FiO2 to select patients with more severe ARDS
for enrollment have become more prevalent. A recent
multicenter, prospective, randomized, controlled trial of
prone positioning in patients with severe ARDS as de-
fined by PaO2/FiO2 < 150 mmHg on PEEP of ≥ 5 showed
that prolonged prone-positioning sessions significantly
decreased mortality in this patient group [6].
Unlike adults, children with ARDS are less likely to
have complicated underlying diseases or other organ
involvement. Thus, Flori et al. showed that the initial
severity of arterial hypoxemia correlated well with ICU
mortality in 328 children with ARDS [39]. Furthermore,
Wong et al. showed that both a low PaO2/FiO2 ratio and
a low SpO2/FiO2 were associated with poor outcomes in
children with ARDS [40].
The Oxygenation Index (OI) is defined as the recipro-
cal of PaO2/FiO2 ratio multiplied by the mean airway
pressure and was originally developed for evaluation of
candidates for extracorporeal membrane oxygenation in
pediatric respiratory failure [41]. The OI has also been
evaluated as a clinical predictor in ARDS. In a study of
149 patients with ARDS undergoing lung protective ven-
tilation, OI was superior to PaO2/FiO2 ratio, and was an
independent predictor of mortality [42]. Similarly, a high
OI at 24 h of ARDS was a risk factor for mortality [40],
and improvement in OI during the first 24 h predicted a
better outcome in pediatric patients with ARDS [43].
Genetic polymorphisms and biomarkers
Polymorphisms
Several factors have made it challenging to determine the
influence of genetic heterogeneity on clinical outcomes in
ARDS. Foremost is the fact that ARDS is a complex clin-
ical syndrome that involves multiple pathogenetic path-
ways and affects a diverse spectrum of patients who often
have comorbid illnesses [3]. Additionally, it has been diffi-
cult to accrue sufficient patient numbers for identification
and validation of genetic risk modifiers with relatively
modest effect sizes. Nevertheless, a variety of genetic poly-
morphisms related to inflammation, innate immunity,
epithelial cell function, and angiogenesis have been re-
ported to be associated with adverse outcomes of ARDS
[15, 44–48] as shown in Table 1. Although a variety of
common polymorphisms are associated with adverse out-
comes in ARDS, such as homozygosity for the 4G allele of
plasminogen activation inhibitor-1 (PAI-1) [49], others
such as polymorphisms in the extracellular superoxide
dismutase gene have been shown to have an association
with better outcomes in ARDS [50]. In addition to the
need for larger validation studies to confirm the observed
associations, substantial additional research is needed to
understand the functional impact of the various candidate
polymorphisms on protein function and expression levels
and how these functional changes contribute to
alterations in ARDS outcomes.
Biomarkers
The pathophysiological hallmarks of ARDS are injury to
the alveolar epithelial, microvascular endothelial barriers
and alveolar-capillary membrane [51], with concomitant
activation of inflammatory and coagulation pathways
[52]. A variety of protein biomarkers have been studied
for their prognostic value in ARDS. For discussion, we
have categorized the most promising potential
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biomarkers into four categories [53], as shown in Table 2
and discussed below.
1. Pulmonary Endothelium
Injury to the pulmonary microvascular bed is a major
pathogenetic feature of ARDS. Endothelial injury causes
increased vascular permeability primarily at the level of
the lung microcirculation, which in turn results in the
accumulation of protein-rich pulmonary edema fluid in
the alveolus [52]. Thus, various mediators of endothelial
activation, injury and permeability have the potential to
be prognostic indicators in ARDS.
Vascular endothelial growth factor (VEGF) promotes
endothelial survival by inhibiting apoptosis in the alveo-
lar capillary membrane. Abadie et al. reported that
VEGF levels in lung tissue obtained by open lung biopsy
from 29 ARDS patients were lower when comparing to a
control group [54]. Furthermore, ARDS patients with el-
evated VEGF levels in lung epithelial lining fluid ob-
tained by bronchoalveolar lavage or VEGF-receptor 2
measured in the serum had a better outcome [55, 56].
Angiopoietin-2 (Ang-2) is an angiogenic factor that
promotes cell death and vascular destabilization. It is re-
leased from endothelial cells in response to endothelial
activation by proinflammatory cytokines or local,
Table 2 Biomarkers associated with mortality in ARDS patients




VEGF 40 Elevated VEGF levels in ELF may predict a
better outcome
[55]
VEGF receptor-2 101 Independently predictive of death [56]
Angiopoietin-2 931 Independently predictive of death [59]
von Willebrand factor 559 Independently predictive of death [60]
Epithelium
Surfactant protein-D 565 Independently predictive of death [62]
ELF KL-6 32 Predictive of death [63]
RAGE 676 Predictive of death [65]
Clara cell protein (CC-16) 78 Predictive of death [69]
Inflammation
LTB4, IL-8 35, 39, 816 Predictive of death [70–72]
IL-2, IL-15 34 Predictive of death [73]
Decoy receptor (DcR) 3 Predictive of death [75]
Ratio of Tregs to all CD4+ lymphocytes in bronchoalveolar
lavage (BAL)
47 Predictive of death [79]
Coagulation
Protein C 45, 779 Predictive of death [83, 84]
PAI-1 779 Predictive of death [84]
Table 1 Polymorphisms associated with mortality in ARDS patients
Gene No. of patients Results Reference
DARC (rs2814778) 132 17 % increase in 60-day mortality [15]
NFE2L2 (rs6721961) 750 Increased 28-day mortality (OR 9.73) [45]
NAMPT (rs61330082) 750 Increased 28-day mortality (OR 4.37) [45]
ADIPOQ (rs208294) 587 Increased mortality (hazard ratio 2.61 [46]
ACE I/D polymorphism, DD type 101 Increase 28-day mortality (OR: 8.8) [47]
VEGF (−460 T + 405C + 936 T) 394 Increase 28-day mortality (OR: 2.89) [48]
GCCT haplotype of EC-SOD 157 Decreased 28-day mortality [50]
PAI-1 4G/5G polymorphism 52 Increase 28-day mortality (OR: 9.95) [49]
ACE angiotensin-converting enzyme, EC-SOD extracellular superoxide dismutase, DARC duffy antigen/receptor for chemokines, VEGF vascular endothelial
growth factor
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environmental factors such as hypoxia [57]. Circulating
angiopoietin-2 levels are associated with permeability
pulmonary edema, and the occurrence and severity of
ARDS in patients with and without sepsis [58]. In 931
subjects with ARDS enrolled in a randomized trial of lib-
eral versus conservative fluid management, higher base-
line angiopoietin-2 levels were strongly associated with
increased mortality in noninfection-related ARDS, but
not in infection-related ARDS, indicating that plasma
angiopoietin-2 has differential prognostic value for mor-
tality depending on the presence or absence of infection
as an ARDS risk factor [59].
Von Willebrand Factor antigen (VWF), a high molecu-
lar weight glycoprotein produced predominantly by
endothelial cells, can be used as a marker of endothelial
activation or injury. In a multicenter study of 559 pa-
tients with ARDS, higher plasma levels of VWF were in-
dependently associated with adverse outcomes,
including mortality, duration of unassisted ventilation,
and organ failures [60]. Taken together, the association
of lower levels of VEGF and higher levels of Ang-2 and
VWF suggests that the extent of endothelial injury is an
important determinant of outcomes from ARDS.
2. Pulmonary Epithelium
Surfactant proteins (SP) are secreted primarily by alveo-
lar epithelial type II pneumocytes, and leakage of surfac-
tant proteins from the alveolar space into the circulation
is a marker of lung epithelial injury [61]. Eisner et al.
showed that baseline SP-D plasma levels were associated
with increased risk of death in 565 patients with ARDS. In
addition, a low tidal volume protective ventilatory strategy
(6 ml/kg) had no effect on the rise in plasma SP-A levels
but attenuated the rise in plasma SP-D levels [62].
KL-6 is a mucin-like glycoprotein expressed on the sur-
face of alveolar type II cells. Damage to pulmonary epithe-
lial cells allows KL6 to diffuse into the pulmonary
epithelial lining fluid (ELF). In a study of 32 patients with
ARDS, ELF was collected using a bronchoscopic micro-
sampling procedure, showing that KL-6 levels in ELF, but
not serum, measured during the early period after the
diagnosis were useful for predicting mortality [63].
The receptor for advanced glycation end products
(RAGE), a member of the immunoglobulin superfamily
that acts as a multi-ligand receptor, has been identified as
a marker of alveolar type I cell injury [64]. In a multicenter
study of 676 patients with ARDS enrolled in a randomized
controlled trial of lower tidal volume ventilation, higher
baseline plasma RAGE was associated with increased se-
verity of lung injury and mortality (OR 1.38) [65].
Clara cell protein (CC-16), an inhibitor of phospholip-
ase A2 activity produced by distal bronchiolar epithelial
cells, has been shown to have a protective and
immunomodulatory role in acute lung injury [66]. In a
retrospective study of 22 patients with ventilator-
associated pneumonia, levels of CC-16 increased 2 days
before ARDS diagnosis [67]. However, Kropski et al.
showed that levels of CC-16 in plasma or edema fluid
were lower in ARDS than in critically ill controls with
cardiogenic pulmonary edema [68]. In a prospective
multicenter observational study from Quebec Critical
Care Network, a higher initial CC-16 serum level was
associated with increased risk of death in 78 adult ARDS
patients [69]. Different time points for obtaining the
CC-16 and variable severity of lung injury may be poten-
tial explanations for these conflicting findings.
3. Inflammatory mediators
Inflammation is fundamental to the pathogenesis of
ARDS and a variety of inflammatory biomarkers have
been assessed for prognostic utility. Among the cyto-
kines, plasma leukotriene (LT) B4, interleukin (IL)-8,
and IL-6 have been recognized as useful prognostic indi-
ces in patients with early phase ARDS [70–72]. In
addition, serum IL-2 and IL-15 levels had shown to be
associated with mortality in patients with ARDS [73].
Decoy receptor (DcR) 3, belonging to the tumor necrosis
factor receptor superfamily, is an antiapoptotic soluble re-
ceptor considered to play a role in immune modulation
[74]. In a study of 88 ARDS patients, high plasma DcR3
levels correlated with development of multiple-organ dys-
function and independently predicted 28-day mortality [75].
T-regulatory cells (Tregs), a subset of CD4+ lympho-
cytes that express CD25 (IL-2 receptor α) as well as the
transcription factor Forkhead box protein 3 (Foxp3) on
their surface, have been shown to suppress inflamma-
tory, allergic, and autoimmune disorders [76, 77].
D’Alessio et al. identified that CD4 + CD25 + Foxp3+
Tregs serve a fundamental role in mediating resolution
of lung injury by modulating innate immune responses
[78]. In a prospective study of 47 patients with ARDS,
the ratio of Tregs to all CD4+ lymphocytes in broncho-
alveolar lavage (BAL) was shown to be an independent
prognostic factor for 30-day mortality [79].
C-reactive protein (CRP) has been studied as a marker of
systemic inflammation and outcome in a number of dis-
eases. In a prospective study of 177 patients with ARDS, in-
creasing plasma levels of CRP within 48 h of ARDS onset
were associated with a better outcome, implying that CRP is
not solely a marker of systemic inflammation [80]. From this
same study cohort, Rivara et al. further showed that elevated
cardiac troponin T (cTnT), a biomarker of cardiac necrosis,
was associated with worsened clinical outcomes and certain
echocardiographic abnormalities in patients with ARDS [81].
4. Coagulation
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Protein C plays an active role in modulating severe
systemic inflammatory processes such as sepsis, and
trauma via its anticoagulant and anti-inflammatory
properties [82]. The first human study regarding protein
C in ARDS, which enrolled 45 patients, showed that
lower levels of plasma protein C were associated with
worse clinical outcomes [83]. Later, in a larger multicen-
ter study of a protective ventilatory strategy in 779 pa-
tients with ARDS, lower plasma levels of protein C were
an independent risk factor for mortality and adverse
clinical outcomes [84]. Based on these findings, Cornet
et al. conducted a randomized control trial of intraven-
ous recombinant human activated protein C for 4 days,
finding that it did not improve outcomes in patients
with ARDS [85]. Similarly, Liu et al. also showed that ac-
tivated protein C did not improve outcomes from ARDS
in a double-blind randomized control trial [86].
Plasminogen activator inhibitor-1 (PAI-1) impairs fi-
brinolysis by inhibiting tissue plasminogen activator
(tPA) and urokinase (uPA). Ware et al. showed that in-
creased plasma levels of PAI-1 are independent risk fac-
tors for mortality in 779 patients with ARDS and that
the combination of low protein C levels with high PAI-1
levels portended a particularly poor prognosis [84].
Although there have been a number of biological
markers investigated for predicting clinical outcomes in
ARDS, no single clinical or biological marker is able to
predict the outcome accurately. Thus, Ware et al. com-
bined eight biological markers and clinical variables to
predict mortality in 549 patients with ARDS from an
NIH ARDS Network clinical trial of two levels of posi-
tive end-expiratory pressure in ARDS. In that study, a
combination of clinical predictors and biomarkers had
the best performance for predicting mortality in patients
with ARDS compared to clinical predictors or bio-
markers alone [13].
Scoring systems
For describing the severity-of-illness and constructing
risk-prediction models in general ICU populations, many
scoring systems have been developed, such as the Acute
Physiology and Chronic Health Evaluation (APACHE)
scores [87–89], the Simplified Acute Physiology Scores
[90] and Sequential Organ Failure Assessment (SOFA)
scoring [91]. APACHE II score is not only accurate for
predicting outcomes in general ICU patients, but also in
patients with ARDS [69, 73]. In addition, the APACHE
IV score, the RIFLE score (Risk of renal failure, Injury to
the kidney, Failure of kidney function, Loss of kidney
function, and End-stage renal failure) [92], and GOCA
score (Gas exchange, Organ failure, Cause, Associated
disease) [93] have all been proved to have prognostic
value in predicting mortality in patients with ARDS.
In terms of scoring systems for predicting mortality spe-
cifically in ARDS patients, the most commonly used is the
Lung Injury Score (LIS), proposed in 1988 by Murray and
colleagues [94]. The Lung Injury Score is based on four
components: 1) chest radiograph; 2) hypoxemia score; 3)
PEEP; and 4) static compliance of respiratory system. Al-
though it was not originally intended as a risk prediction
tool, it has been widely used to assess ARDS severity in
clinical studies. However, some studies showed that LIS
was not independently associated with in-hospital mortal-
ity in ARDS patients [8, 11, 13] when ARDS was defined
by AECC criteria [2]. By contrast, in a multi-ICU cohort
study with 550 ARDS patients diagnosed by Berlin defin-
ition, the LIS was associated with increased in-hospital
morbidity and mortality [95].
Conclusions
ARDS is a complex and heterogeneous syndrome. A var-
iety of clinical and biomarker parameters can be used
for risk prediction and prognostication. Discovery of
prognostic factors for ARDS has enriched our under-
standing of the pathogenesis of this complex clinical
syndrome and has impacted clinical trial design, risk as-
sessment and accurate diagnosis of the syndrome. In this
review, we categorized the prognostic factors into four
areas including (1) clinical characteristics (2) physio-
logical parameters and oxygenation (3) genetic polymor-
phisms and biomarkers (4) scoring systems. In terms of
clinical characteristics, age and severity of illness scores
remain the most robust predictors of outcome while
blood type, race and ethnicity may be novel predictors of
death in ARDS that require further validation. Pulmon-
ary dead space, ratio of right over left ventricular stroke
work, PaO2/FiO2 ratio, and oxygenation index are
proven to be independent predictors of mortality. A
number of genetic polymorphisms have been shown to
be associated with mortality in ARDS, in genes including
angiotensin-converting enzyme, extracellular superoxide
dismutase, duffy antigen/receptor for chemokines, and
vascular endothelial growth factor. A variety of biomarkers
involved in the pathogenesis of endothelial and epithelial
injury, inflammatory response and coagulation have been
explored. Scoring systems such as APACHE II, GOCA,
LIS, and RIFLE score are reliable in predicting mortality in
ARDS. Finally, prognostic factors differ for predicting
short-term and long-term outcomes, and may differ de-
pending on treatment including low tidal volume, prone
position or ECMO intervention. Thus, recent changes in
definitions [1] and ventilatory strategies [9] should be
taken into account in interpreting older prognostic studies
that preceded the low tidal volume era.
Based on the prognostic factors mentioned above, we
may better determine subphenotypes of ARDS. Incorp-
orating these distinctions into clinical trial design may
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allow more effective treatment selection for a particular
ARDS phenotype in the future. For example, Calfee et
al. showed that ARDS patients with a hyperinflammatory
subphenotype identified by latent class analysis of a
combination of clinical characteristics and plasma bio-
markers had worse clinical outcomes and differential re-
sponses to ventilator interventions in two large cohorts
[96]. Briel et al. showed that patients with moderate or
severe ARDS, but not mild ARDS had an improved hos-
pital survival when using a higher level of PEEP [97].
Guérin et al. found that only in patients with severe
ARDS, but not moderate or mild ARDS, early applica-
tion of prolonged prone-positioning sessions signifi-
cantly decreased 28-day and 90-day mortality [6]. These
studies illustrate the potential for use of prognostic fac-
tors including clinical factors such as oxygenation and
biological markers for better selecting patients for en-
rollment in ARDS clinical trials.
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